Matters of the Heart: Cardiotoxicity Related to Target Therapy in Oncogene-Addicted Non-Small Cell Lung Cancer [PDF]
The treatment of Non Small Cell Lung Cancer (NSCLC) has been revolutionised by the introduction of targeted therapies. With the improvement of response and frequently of overall survival, however, a whole new set of adverse events emerged.
Bearz A. +7 more
core +1 more source
Expanded Access Program Pralsetinib in Advanced Non–Small Cell Lung Cancer with Rearranged during Transfection (RET) Gene Rearrangement [PDF]
, 2023 Youngkyung Jeon +7 more
openalex +1 more source
A case of organizing pneumonia in rearranged during transfection fusion-positive lung adenocarcinoma treated with selpercatinib [PDF]
Selpercatinib is the first targeted therapy for rearranged during transfection (RET)fusion-positive unresectable non-small-cell lung cancer (NSCLC).
18160 +45 more
core +1 more source
Cabozantinib, Vandetanib, Pralsetinib and Selpercatinib as Treatment for Progressed Medullary Thyroid Cancer with a Main Focus on Hypertension as Adverse Effect [PDF]
, 2023 Linnea Højer Wang +5 more
openalex +1 more source
Kinase Inhibitors FDA-Approved 2018-2023: Drug Targets, Metabolic Pathways, and Drug-Induced Toxicities [PDF]
Small molecule kinase inhibitors are one of the fastest growing classes of drugs, which are approved by the US Food and Drug Administration (FDA) for cancer and noncancer indications.
Geffert, Raeanne M +2 more
core +2 more sources
Efficacy and safety of pralsetinib in patients with advanced RET fusion‐positive non–small cell lung cancer [PDF]
, 2023 Qing Zhou +17 more
openalex +1 more source
Analytical Method Development and Validation of Selpercatinib in Pure and Pharmaceutical Dosage Form by RP-HPLC [PDF]
A robust and sensitive reversed-phase high-performance liquid chromatography (RP-HPLC) method was developed and validated for the estimation of Selpercatinib in pure and pharmaceutical formulations. The method uses a C18 column with a mobile phase of 0.2%
Madhvilatha, Jonnakuti +2 more
core +2 more sources